Sökning: onr:"swepub:oai:DiVA.org:liu-200753" >
Minimal residual di...
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
-
- Nahi, Hareth (författare)
- Linköpings universitet,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US,Karolinska Inst, Sweden
-
- Afram, Gabriel (författare)
- Karolinska Inst, Sweden
-
- Uttervall, Katarina (författare)
- Karolinska Institutet
-
visa fler...
-
- Lockmer, Sandra (författare)
- Karolinska Inst, Sweden
-
- Tätting, Love, 1988- (författare)
- Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US
-
- Gahrton, Gosta (författare)
- Karolinska Inst, Sweden
-
- Kashif, Muhammad (författare)
- Karolinska Inst, Sweden; Karolinska Inst, Sweden
-
- Alici, Evren (författare)
- Karolinska Inst, Sweden
-
- Stromberg, Olga (författare)
- Dept Med, Sweden
-
- Klimkowska, Monika (författare)
- Karolinska Institutet
-
- Lund, Johan (författare)
- Karolinska Inst, Sweden
-
visa färre...
-
(creator_code:org_t)
- WILEY, 2023
- 2023
- Engelska.
-
Ingår i: Cancer Medicine. - : WILEY. - 2045-7634. ; 12:22, s. 20736-20744
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: The presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression-free survival (PFS) and overall survival (OS).Methods: At our department, we recommend lenalidomide maintenance for patients who are MRD+ after ASCT, while MRD-negative (MRD-) patients, after information about the national guidelines, were not advised to follow this regimen.Results: Out of the total 228 patients, 175 received ASCT following first-line induction (MRD- 92 (53%), MRD+ 83 (47%), at 2 months post-ASCT), while 53 underwent ASCT after second-line treatment (MRD- 27 (51%), MRD+ 26 (49%), at the same time point). Comparatively, MRD- patients who did not receive maintenance demonstrated better OS than MRD+ patients who received upfront ASCT and maintenance treatment (96% vs. 86%, p = 0.030, at 3 years). However, nonsignificant difference was found in PFS (76% vs. 62%, at 3 years). Furthermore, second-line ASCT, MRD- non-maintained patients exhibited significantly better PFS than MRD+ (71% vs. 27%, p > 0.001, at 3 years). However, OS was better but nonsignificant (96% vs. 76%, at 3 years). Fluorescence in situ hybridization (FISH) analysis was performed on 141 out of the 228 patients. Of these, 85 (60%) patients were deemed standard risk (SR), and 56 (40%) were classified as high risk (HR). In the SR cohort, MRD- patients exhibited better PFS and OS than MRD+ patients (71% vs. 59% and 100% vs. 85%, respectively). In the HR cohort, the MRD- patients showed superior PFS but similar OS compared to MRD+ patients (66% vs. 42% and 81% vs. 80%, respectively).Conclusions: Our results indicate that being MRD- is a more crucial prognostic factor for the 3-year PFS and OS than the presence of high-risk cytogenetic markers or undergoing maintenance treatment. The latter appears insufficient, particularly for MRD+ patients following ASCT in the second-line setting, suggesting that these patients may require a more intensive treatment approach.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- minimum residual disease; multiple myeloma prognosis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nahi, Hareth
-
Afram, Gabriel
-
Uttervall, Katar ...
-
Lockmer, Sandra
-
Tätting, Love, 1 ...
-
Gahrton, Gosta
-
visa fler...
-
Kashif, Muhammad
-
Alici, Evren
-
Stromberg, Olga
-
Klimkowska, Moni ...
-
Lund, Johan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Cancer Medicine
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet